Show simple item record

dc.contributor.authorRobert, C
dc.contributor.authorKaraszewska, B
dc.contributor.authorSchachter, J
dc.contributor.authorRutkowski, P
dc.contributor.authorMackiewicz, A
dc.contributor.authorStroiakovski, D
dc.contributor.authorLichinitser, M
dc.contributor.authorDummer, R
dc.contributor.authorGrange, F
dc.contributor.authorMortier, L
dc.contributor.authorChiarion-Sileni, V
dc.contributor.authorDrucis, K
dc.contributor.authorKrajsova, I
dc.contributor.authorHauschild, A
dc.contributor.authorLorigan, Paul C
dc.contributor.authorWolter, P
dc.contributor.authorLong, G
dc.contributor.authorFlaherty, K
dc.contributor.authorNathan, P
dc.contributor.authorRibas, A
dc.contributor.authorMartin, A
dc.contributor.authorSun, P
dc.contributor.authorCrist, W
dc.contributor.authorLegos, J
dc.contributor.authorRubin, S
dc.contributor.authorLittle, S
dc.contributor.authorSchadendorf, D
dc.date.accessioned2015-02-25T11:54:48Z
dc.date.available2015-02-25T11:54:48Z
dc.date.issued2015-01-01
dc.identifier.citationImproved overall survival in melanoma with combined dabrafenib and trametinib. 2015, 372 (1):30-9 N Engl J Meden
dc.identifier.issn1533-4406
dc.identifier.pmid25399551
dc.identifier.doi10.1056/NEJMoa1412690
dc.identifier.urihttp://hdl.handle.net/10541/345293
dc.description.abstractThe BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.
dc.language.isoenen
dc.rightsArchived with thanks to The New England journal of medicineen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAged, 80 and over
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshImidazoles
dc.subject.meshIndoles
dc.subject.meshIntention to Treat Analysis
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshMale
dc.subject.meshMelanoma
dc.subject.meshMiddle Aged
dc.subject.meshMitogen-Activated Protein Kinase Kinases
dc.subject.meshMutation
dc.subject.meshOximes
dc.subject.meshProtein Kinase Inhibitors
dc.subject.meshProto-Oncogene Proteins B-raf
dc.subject.meshPyridones
dc.subject.meshPyrimidinones
dc.subject.meshSkin Neoplasms
dc.subject.meshSulfonamides
dc.subject.meshSurvival Analysis
dc.subject.meshYoung Adult
dc.titleImproved overall survival in melanoma with combined dabrafenib and trametinib.en
dc.typeArticleen
dc.contributor.departmentGustave Roussy and INSERM Unité 981, Villejuif-Paris Suden
dc.identifier.journalThe New England Journal of Medicineen
html.description.abstractThe BRAF inhibitors vemurafenib and dabrafenib have shown efficacy as monotherapies in patients with previously untreated metastatic melanoma with BRAF V600E or V600K mutations. Combining dabrafenib and the MEK inhibitor trametinib, as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.


This item appears in the following Collection(s)

Show simple item record